Helix Acqsn II SEC Filings

Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics, Inc.) completed an IPO structure that placed $184,000,000 into a trust account and converted sponsor/founder Class B shares through a series of share capitalizations, resulting in 4,600,000 Class B ordinary shares held by the Sponsor and certain directors and advisors. The underwriter fully exercised its over-allotment on February 13, 2024, removing forfeiture conditions from 600,000 Founder Shares.

The filing discloses early-stage clinical programs for BBOT including BBO-8520 (ONKORAS-101), BBO-11818 (IND submitted Q1 2025; enrollment began March 2025) and BBO-10203 (BREAKER-101 dose escalation). Management expects interim ONKORAS-101 data in H2 2025 and early BREAKER-101 data in H1 2026. At December 31, 2024 the company reported $1,697,777 in cash and working capital of $1,762,262 and the auditor noted substantial doubt about going concern. The prospectus details business combination mechanics, trust protections, manufacturing and IP risks, and related-party and compensation disclosures.

BridgeBio Oncology Therapeutics, Inc. (BBOT) reported a Form 4 filing showing that Praveen P. Tipirneni, a company director, was granted a stock option on 08/26/2025. The option is a right to buy 52,269 shares of common stock at an exercise price of $9.59 per share. The option award is held directly by the reporting person and is recorded as acquired (Transaction Code A). The award includes a vesting schedule tied to an August 11, 2025 vesting commencement date where a fractional portion vests upon effectiveness of a Form S-8 registration statement and then vests monthly over 48 months until fully vested on the fourth anniversary, subject to continuous service.

The filing is signed on behalf of the reporting person by an attorney-in-fact on 08/28/2025.

Frank McCormick, a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), was granted a stock option to purchase 91,076 shares of common stock with an exercise price of $9.59 per share. The option was reported with a transaction date of 08/26/2025 and an expiration date of 08/25/2035. Vesting is governed by a schedule that begins on a Vesting Commencement Date of 08/11/2025: a fractional portion vests on the date an S-8 registration is filed and becomes effective, then 1/48th vests monthly thereafter until fully vested on the fourth anniversary, subject to continuous service. The Form 4 was signed by an attorney-in-fact on 08/28/2025.

BridgeBio Oncology Therapeutics, Inc. director Jake Bauer reported acquisition of a stock option on 08/26/2025. The Form 4 discloses a grant (transaction code A) of a Stock Option (Right to Buy) covering 138,193 underlying shares of Common Stock with an exercise price of $9.59. The form shows 138,193 derivative securities beneficially owned following the transaction and lists the option as direct ownership. The table includes a date field of 08/25/2035 in the exercisable/expiration column. The filing includes a vesting description: vesting is tied to an S-8 filing and then monthly vesting over a 48-month schedule measured from an April 25, 2025 vesting commencement date. The Form 4 was signed by an attorney-in-fact on 08/28/2025.

BridgeBio Oncology Therapeutics, Inc. (BBOT) reporting person Pedro Beltran, identified as an officer (Chief Scientific Officer) and director, received an option grant on 08/26/2025 to purchase 357,177 shares of common stock at an exercise price of $9.59 per share. The option is reported as acquired and is classified as a stock option with an expiration or reference date of 08/25/2035. Vesting begins from a Vesting Commencement Date of 08/11/2025: a pro rata fraction vests upon effectiveness of a Form S-8 registration and thereafter 1/48th vests monthly, completing over four years, subject to continuous service. The form is signed by an attorney-in-fact on 08/28/2025.

BridgeBio Oncology Therapeutics reported an insider award to its Chief Medical & Development Officer and director, Ben Yong. The Form 4 discloses an award of a stock option to purchase 357,177 shares of common stock at an exercise price of $9.59. The option grant is exercisable consistent with a time-based vesting schedule: vesting commences from an August 11, 2025 vesting commencement date, with an initial fractional vesting linked to the date a Form S-8 registration is filed and becomes effective and then monthly vesting thereafter until fully vested on the fourth anniversary of the vesting commencement date, subject to continuous service. Following the reported transaction the reporting person directly beneficially owns 357,177 shares underlying the option.

BridgeBio Oncology Therapeutics, Inc. (BBOT) reported an insider acquisition on Form 4 filed for reporting person Wallace Eli M., who is listed as both a director and the Chief Executive Officer. On 08/26/2025 the reporting person acquired a stock option to purchase 499,731 shares at an exercise price of $9.59. The option is subject to a time-based vesting schedule beginning August 11, 2025, with vesting over 48 months and a portion tied to the effectiveness of an S-8 registration; the full grant vests on the fourth anniversary of the vesting commencement date, subject to continued service. The Form 4 was signed by an attorney-in-fact on 08/28/2025.

Mehra Uneek, Chief Financial Officer and director of BridgeBio Oncology Therapeutics, Inc. (ticker BBOT), reported the acquisition of 633,570 stock options on 08/26/2025. The options have an exercise price of $9.59 and are held directly by the reporting person, leaving 633,570 options beneficially owned following the transaction. The filing is signed by an attorney-in-fact on 08/28/2025. Under the grant terms, 25% of the underlying shares vest on July 21, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to continued service. The instrument is a standard stock option intended to align executive compensation with shareholder value.

BridgeBio Oncology Therapeutics, Inc. is reported as having material passive ownership by multiple Deerfield entities and James E. Flynn. The filing states Deerfield Partners, Deerfield Private Design Fund V, Deerfield Mgmt, L.P. and Deerfield Mgmt V, L.P. each report ownership of 2,442,723 shares (3.08% of the class). Deerfield Management Company, L.P. and James E. Flynn each report aggregate beneficial ownership of 4,885,446 shares (6.17% of the class). All reporting persons state no sole voting or dispositive power and report shared voting and dispositive power only. The filing includes joint filing, item 8 exhibits, and a power of attorney.